Review
Pathology
Gaetano Paolino, Liron Pantanowitz, Valeria Barresi, Fabio Pagni, Enrico Munari, Lorenzo Moretta, Matteo Brunelli, Elena Bariani, Elena Vigliar, Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone, Ilaria Girolami, Albino Eccher
Summary: Studies suggest a underestimation of PD-L1 expression in biopsies compared to resection specimens, with higher positivity in metastatic lymph nodes. The therapy has conflicting effects on PDL1 expression. The most recent patient material related to the natural history of tumor may be the most reliable for evaluating PD-L1 expression.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Bregje M. Koomen, Quirinus J. M. Voorham, Chantal C. H. J. Epskamp-Kuijpers, Carmen van Dooijeweert, Anne S. R. van Lindert, Ivette A. G. Deckers, Stefan M. Willems
Summary: The study assessed the interlaboratory variation in PD-L1 positivity in the Netherlands, revealing significant differences between labs, especially with the 1% cutoff. The analysis showed that cytology data had a higher degree of variation compared to histology data when using the 50% cutoff.
Review
Medicine, General & Internal
Bojana Gutic, Tatjana Bozanovic, Aljosa Mandic, Stefan Dugalic, Jovana Todorovic, Dejana Stanisavljevic, Miroslava Gojnic Dugalic, Demet Sengul, Dzenana A. Detanac, Ilker Sengul, Dzemail Detanac, Jose Maria Soares Junior
Summary: Programmed Cell Death-1 (PCD-1) is an immune checkpoint receptor mainly found on various activated immune cells. Its interaction with Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2) plays a crucial role in inhibitory signaling and immune tolerance. PD-L1 expression, determined by Immunohistochemistry (IHC), has shown prognostic and therapeutic potential in cancer treatment, serving as a predictive biomarker for PD-1/PD-L1 inhibitor response. Therefore, checkpoint blockades targeting PCD-1/PD-L1 axis have been registered as a treatment option for different types of cancer.
Review
Pathology
Paul W. Harms, Timothy L. Frankel, Myrto Moutafi, Arvind Rao, David L. Rimm, Janis M. Taube, Dafydd Thomas, May P. Chan, Liron Pantanowitz
Summary: Our understanding of human disease has evolved greatly in recent decades, particularly in the areas of immunology and cancer treatment. Advances in digital pathology have opened new avenues for studying the tumor microenvironment. Traditional tissue-based evaluations are limited in their ability to analyze complex quantitative data and multiple biomarkers, making multiplex staining techniques a promising alternative.
Article
Oncology
Kang Hee Shim, Ji Eun Kwon, Sung Gon Park, Seol Ho Choo, Se Joong Kim, Sun Il Kim
Summary: This study conducted a systematic analysis of PD-L1 expression in prostate cancer patients, revealing that 15% and 46% of biopsy cores were positive for mPD-L1 and nPD-L1, respectively. There was a positive correlation between Gleason score and mPD-L1, and a negative correlation between Gleason score and nPD-L1, with no significant correlation between mPD-L1 and nPD-L1. Additionally, both mPD-L1 and nPD-L1 expression were not predictive of BCR-free survival.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Henrik Failmezger, Harald Hessel, Ansh Kapil, Guenter Schmidt, Nathalie Harder
Summary: Identifying new tumor biomarkers is crucial in cancer research. Our novel approaches for quantitatively scoring spatial marker expression heterogeneity outperform expression averages, showing the importance of considering spatial variability in tumor biology research.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Tomoki Nishida, Yuji Matsumoto, Shinji Sasada, Midori Tanaka, Toshiyuki Nakai, Ryuta Fukai, Yuichiro Ohe, Shun-Ichi Watanabe, Noriko Motoi
Summary: The study showed a high concordance in immunohistochemical expression of certain tumor markers between cryobiopsy and conventional scalpel sampling in lung cancer lesions. While most cases exhibited consistent results, some differences in PD-L1 tumor proportion scores between sample types were potentially due to intratumoral heterogeneity.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Dentistry, Oral Surgery & Medicine
Daniel Lenouvel, Miguel Angel Gonzalez-Moles, Isabel Ruiz-Avila, Clara Chamorro-Santos, Lucia Gonzalez-Ruiz, Isabel Gonzalez-Ruiz, Pablo Ramos-Garcia
Summary: PD-L1 expression is more common in non-smokers and non-drinkers, particularly in tongue squamous cell carcinomas. The presence of PD-L1 is also associated with increased lymphocyte infiltration and staining in the adjacent epithelium of the tumour invasion area.
Article
Urology & Nephrology
Paul Toren, Herve Brisson, David Simonyan, Helene Hovington, Louis Lacombe, Alain Bergeron, Yves Fradet
Summary: The impact of sex hormones, specifically androgens via the androgen receptor, on cancer immunotherapy is still controversial. Expression of AR in bladder tumors may affect the success of immune checkpoint blockade, while high immune cell PD-L1 expression is associated with higher stage and grade of tumors. The study suggests that AR expression and immune checkpoint expression play different roles in non-muscle invasive and muscle-invasive bladder cancer outcomes.
WORLD JOURNAL OF UROLOGY
(2021)
Article
Oncology
Rogier Butter, Liesbeth M. Hondelink, Lisette van Elswijk, Johannes L. G. Blaauwgeers, Elisabeth Bloemena, Rieneke Britstra, Nicole Bulkmans, Anna Lena van Gulik, Kim Monkhorst, Mathilda J. de Rooij, Ivana Slavujevic-Letic, Vincent T. H. B. M. Smit, Ernst-Jan M. Speel, Erik Thunnissen, Jan H. von der Thusen, Wim Timens, Marc J. van de Vijver, David C. Y. Yick, Aeilko H. Zwinderman, Danielle Cohen, Nils A. 't Hart, Teodora Radonic
Summary: This study demonstrates the impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of immunostaining in the context of PD-L1 in NSCLC.
Article
Gastroenterology & Hepatology
Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Akinobu Takaki, Masahiro Takahara, Hironari Kato, Ryuichi Yoshida, Yuzo Umeda, Takahito Yagi, Akihiro Matsukawa, Hiroyuki Okada
Summary: This study evaluated whether biopsy specimens could predict the positive status of PD-L1 in surgically resected tissue. The results showed a substantial positive and high negative concordance rates between biopsy samples and surgically resected tissues in terms of PD-L1 expression.
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Review
Pharmacology & Pharmacy
Kenneth Emancipator
Summary: The clinical development of pembrolizumab showed that PD-L1 expression level is a biomarker for patient response and cancer outcome, lowering the threshold for PD-L1 positivity expanded the patient population, and immune cell PD-L1 expression plays an important role in predicting tumor response in patients treated with pembrolizumab.
Review
Medicine, General & Internal
Moonsik Kim, Ji Yun Jeong, An Na Seo
Summary: Gastric cancer is the third leading cause of cancer-related death worldwide, and molecular heterogeneity and acquired resistance are major barriers to biomarker-guided targeted therapies. However, the recent emergence of immunotherapy has shown promising survival benefits in some studies, particularly with immune checkpoint inhibitors (ICIs) targeting inhibitory receptors on T lymphocytes. This article reviews the predictive biomarkers, with a focus on PD-L1 expression, that affect the response to ICIs in gastric cancer.
Article
Oncology
Jing Qin, Bo Chen, Chenghui Li, Junrong Yan, Hongyang Lu
Summary: Genetic heterogeneity and predictive biomarkers were investigated in patients with pulmonary sarcomatoid carcinoma (PSC). The study found common mutations between the carcinomatous and sarcomatous components, as well as significantly higher PD-L1 expression in the carcinomatous components. High PD-L1 expression suggests potential efficacy of immunotherapy for PSC patients, emphasizing the importance of genetic alteration and PD-L1 expression detection in treatment.
Article
Medicine, General & Internal
Kazuhiko Hashimoto, Shunji Nishimura, Naoki Sakata, Masami Inoue, Akihisa Sawada, Masao Akagi
Summary: Recent data suggest that PD-1 and PD-L1 are involved in the pathogenesis of Langerhans cell histiocytoma (LCH), with high expression rates observed in musculoskeletal LCH cases. This study evaluated PD-1/PD-L1 expression in 6 patients with musculoskeletal LCH, finding potential roles for these immune checkpoint molecules in the disease microenvironment.
